Clinical Trials Logo
  1. Home
  2. Peripheral Neuropathy
  3. NCT01611155

Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

Peripheral Neuropathy Clinical Trial

Official title:
A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy

Clinical Trial Summary

You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of venlafaxine with a placebo (an inactive agent) on oxaliplatin-induced neuropathy (numbing, tingling and/or pain)

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To explore whether venlafaxine can prevent or ameliorate chronic, cumulative neurotoxicity associated with oxaliplatin in cancer patients receiving oxaliplatin, fluorouracil, leucovorin calcium (FOLFOX).

SECONDARY OBJECTIVES:

I. To explore whether venlafaxine can ameliorate acute neuropathy associated with oxaliplatin.

TERTIARY OBJECTIVES:

I. To explore whether venlafaxine can increase the cumulative oxaliplatin doses that can be delivered without dose-limiting chronic neurotoxicity.

II. To explore whether venlafaxine causes adverse events in this setting. III. To explore whether the neuropathy data provided by the Rydel-Seiffer graduated tuning fork is consistent with patient-reported outcome (PRO) measures of chemotherapy-induced peripheral neuropathy (CIPN) and whether this tool might cause different results in patients receiving venlafaxine versus placebo.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive venlafaxine orally (PO) twice daily (BID) beginning on day 1 of and continuing through completion of FOLFOX.

ARM II: Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.

After completion of study treatment, patients are followed up at 1, 3, 6, 12, and 18 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01611155
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase N/A
Start date February 17, 2012
Completion date September 23, 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05152368 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy Phase 1
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Completed NCT02549534 - Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer N/A
Active, not recruiting NCT02701075 - MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain N/A
Completed NCT01196442 - Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer N/A
Completed NCT00763087 - Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet N/A
Completed NCT00079807 - Painful HIV Neuropathy and Alpha-Lipoic Acid Phase 1/Phase 2
Completed NCT03292328 - Yoga for Symptoms of Nerve Damage Caused by Chemotherapy N/A
Active, not recruiting NCT05379140 - Use Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With HIV N/A
Recruiting NCT05673746 - Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer N/A
Completed NCT05189535 - "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" Phase 2/Phase 3
Recruiting NCT06219590 - Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy N/A
Enrolling by invitation NCT05595109 - Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients Phase 2/Phase 3
Completed NCT05916118 - Exercise and Oxaliplatin-induced Peripheral Neuropathy N/A
Withdrawn NCT03881748 - Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy N/A
Not yet recruiting NCT03112057 - Visualize Nociceptor Changes in Neuropathic Human N/A
Completed NCT02936843 - Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Phase 2/Phase 3
Terminated NCT01458015 - Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain Phase 4
Completed NCT01006408 - Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy N/A
Completed NCT00471445 - Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Phase 3